These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 22242928

  • 1. Treatment failure with new hepatitis C drugs.
    Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P.
    Expert Opin Pharmacother; 2012 Feb; 13(3):313-23. PubMed ID: 22242928
    [Abstract] [Full Text] [Related]

  • 2. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T, Marcellin P.
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of chronic hepatitis viral C: new associations].
    Ouzan D.
    Presse Med; 2013 Jun; 42(6 Pt 1):977-82. PubMed ID: 23021659
    [Abstract] [Full Text] [Related]

  • 4. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
    Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.
    Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568
    [Abstract] [Full Text] [Related]

  • 5. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P, Reddy KR.
    Antivir Ther; 2011 Mar; 16(8):1187-201. PubMed ID: 22155901
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
    Pawlotsky JM.
    Hepatology; 2011 May; 53(5):1742-51. PubMed ID: 21374691
    [Abstract] [Full Text] [Related]

  • 9. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
    Asselah T, Marcellin P.
    Liver Int; 2012 Feb; 32 Suppl 1():88-102. PubMed ID: 22212578
    [Abstract] [Full Text] [Related]

  • 10. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S, Solas C, Motte A, Moreau J, Borentain P, Mokhtari S, Botta-Fridlund D, Dhiver C, Portal I, Ruiz JM, Ravaux I, Bregigeon S, Poizot-Martin I, Stein A, Gérolami R, Brouqui P, Tamalet C, Colson P.
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, CUPIC Study Group.
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [Abstract] [Full Text] [Related]

  • 12. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A, Serfaty L.
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [Abstract] [Full Text] [Related]

  • 13. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
    Forestier N, Zeuzem S.
    Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
    [Abstract] [Full Text] [Related]

  • 14. New treatments for chronic hepatitis C virus infection.
    Corouge M, Pol S.
    Med Mal Infect; 2011 Nov; 41(11):579-87. PubMed ID: 21764234
    [Abstract] [Full Text] [Related]

  • 15. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
    Wyles DL, Gutierrez JA.
    J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
    [Abstract] [Full Text] [Related]

  • 16. Telaprevir for the treatment of chronic hepatitis C infection.
    Muir AJ.
    Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
    Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.
    J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
    [Abstract] [Full Text] [Related]

  • 18. Future perspectives: towards interferon-free regimens for HCV.
    Gane E.
    Antivir Ther; 2012 Jan; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [Abstract] [Full Text] [Related]

  • 19. Optimal treatment with boceprevir for chronic HCV infection.
    Maasoumy B, Manns MP.
    Liver Int; 2013 Feb; 33 Suppl 1():14-22. PubMed ID: 23286841
    [Abstract] [Full Text] [Related]

  • 20. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P, Ho E, Francque S.
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.